A phase I, open-label, multiple dose study to assess the tolerability, pharmacokinetics and pharmacodynamics of ARRY-142886 given on a daily oral regime in subjects with advanced solid malignancies

Trial Profile

A phase I, open-label, multiple dose study to assess the tolerability, pharmacokinetics and pharmacodynamics of ARRY-142886 given on a daily oral regime in subjects with advanced solid malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Dec 2006 Status change
    • 19 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top